BRPI0916622A2 - derivados de piperazina usados como moduladores de canal de cálcio cav2,2 - Google Patents

derivados de piperazina usados como moduladores de canal de cálcio cav2,2

Info

Publication number
BRPI0916622A2
BRPI0916622A2 BRPI0916622-0A BRPI0916622A BRPI0916622A2 BR PI0916622 A2 BRPI0916622 A2 BR PI0916622A2 BR PI0916622 A BRPI0916622 A BR PI0916622A BR PI0916622 A2 BRPI0916622 A2 BR PI0916622A2
Authority
BR
Brazil
Prior art keywords
cav2
calcium channel
piperazine derivatives
channel modulators
derivatives used
Prior art date
Application number
BRPI0916622-0A
Other languages
English (en)
Inventor
John Beswick Paul
Campbell Alister
Peter Cridland Andrew
James Gleave Robert
Paul Heer Jag
Hubert Nicholson Neville
William Page Lee
Vile Sadie
Original Assignee
Convergence Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals Limited filed Critical Convergence Pharmaceuticals Limited
Publication of BRPI0916622A2 publication Critical patent/BRPI0916622A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de piperazina usados como moduladores de canal de cálcio cav2,2 a presente invenção se refere a novos derivados de piperazina; a processos para a 5 preparação dos mesmos; a composições farmacêuticas contendo os derivados; e ao uso dos derivados em terapia para tratar doenças para as quais o bloqueio dos canais de cálcio cav2,2 é benéfico.
BRPI0916622-0A 2008-07-17 2009-07-15 derivados de piperazina usados como moduladores de canal de cálcio cav2,2 BRPI0916622A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0813142.7 2008-07-17
GBGB0813142.7A GB0813142D0 (en) 2008-07-17 2008-07-17 Novel compounds
PCT/EP2009/059012 WO2010007073A1 (en) 2008-07-17 2009-07-15 Piperazine derivatives used as cav2.2 calcium channel modulators

Publications (1)

Publication Number Publication Date
BRPI0916622A2 true BRPI0916622A2 (pt) 2019-04-09

Family

ID=39737239

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916622-0A BRPI0916622A2 (pt) 2008-07-17 2009-07-15 derivados de piperazina usados como moduladores de canal de cálcio cav2,2

Country Status (19)

Country Link
US (3) US8288388B2 (pt)
EP (2) EP2300432B1 (pt)
JP (2) JP5543966B2 (pt)
KR (1) KR101599087B1 (pt)
CN (1) CN102099337B (pt)
AR (1) AR072809A1 (pt)
AU (1) AU2009272762B2 (pt)
BR (1) BRPI0916622A2 (pt)
CA (1) CA2730471C (pt)
EA (1) EA018621B1 (pt)
ES (2) ES2396962T3 (pt)
GB (1) GB0813142D0 (pt)
IL (1) IL210446A (pt)
MX (1) MX2011000600A (pt)
PL (1) PL2300432T3 (pt)
TW (1) TW201016677A (pt)
UY (1) UY31990A (pt)
WO (2) WO2010007072A1 (pt)
ZA (1) ZA201100014B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB201000685D0 (en) * 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
EP2665729B1 (en) * 2011-01-19 2015-04-01 Convergence Pharmaceuticals Limited Piperazine derivatives as cav2.2 calcium channel blockers
JP6116555B2 (ja) 2011-06-27 2017-04-19 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー フッ素化アリールアルキルアミノカルボキサミド誘導体
CN106458955B (zh) * 2014-04-14 2019-07-19 格吕伦塔尔有限公司 芳基取代的杂环基砜
EP3131894A1 (en) 2014-04-14 2017-02-22 Grünenthal GmbH Heteroaryl substituted heterocyclyl sulfones
GB201516183D0 (en) * 2015-09-14 2015-10-28 Calchan Ltd Novel pharmaceutical composition
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
KR102654466B1 (ko) * 2017-04-26 2024-04-08 카비온, 인코포레이티드 기억 및 인지 개선 방법 및 기억 및 인지 장애 치료 방법
CN118085389B (zh) * 2024-03-11 2024-11-05 伟建实业(苏州)有限公司 一种环保型抗菌海绵及其制备方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006371A1 (fr) 1987-02-13 1988-08-25 Mitsubishi Denki Kabushiki Kaisha Demarreur/chargeur pour moteurs
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5498711A (en) 1993-02-03 1996-03-12 Thiokol Corporation Synthesis of 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo[5.5.0.05,903,11]dodecane
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
PL185544B1 (pl) 1995-02-13 2003-05-30 Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
WO1996031501A1 (en) 1995-04-07 1996-10-10 Schering Corporation Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
FR2744450A1 (fr) 1996-02-02 1997-08-08 Pf Medicament Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
DK1288206T3 (da) 1996-04-12 2008-11-24 Searle Llc Substituerede benzensulfonamidderivater som prolægemidler af COX-2-inhibitorer
US5880128A (en) 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
EE03680B1 (et) 1996-07-18 2002-04-15 Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
WO1998017625A1 (en) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Novel remedies for infectious diseases
GB9623283D0 (en) 1996-11-08 1997-01-08 Zeneca Ltd Heterocyclic derivatives
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
ATE334975T1 (de) 1997-05-30 2006-08-15 Takeda Pharmaceutical Sulfonamidderivate, ihre herstellung und verwendung
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE317845T1 (de) 1997-09-05 2006-03-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
WO1999037304A1 (en) 1998-01-27 1999-07-29 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
AU772477B2 (en) 1998-08-28 2004-04-29 Scios Inc. Inhibitors of p38-alpha kinase
WO2000026216A1 (en) 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors
EP1140862A4 (en) 1998-12-23 2004-07-28 Bristol Myers Squibb Pharma Co THROMBIN OR Xa FACTOR INHIBITORS
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
JP2002538157A (ja) 1999-02-27 2002-11-12 グラクソ グループ リミテッド ピラゾロピリジン
GB9927844D0 (en) 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
AU2001241927A1 (en) 2000-02-28 2001-09-12 Scios Inc. Inhibitors of p38-alpha kinase
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
WO2001076693A1 (en) 2000-04-10 2001-10-18 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2812198B1 (fr) 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
EP1389204A4 (en) 2001-04-26 2005-03-23 Kolon Inc NEW SULPHONAMIDE DERIVATIVES, THEIR INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS
DE10155684A1 (de) 2001-11-13 2003-05-22 Bayer Ag Thiazolharnstoffe
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
ATE395343T1 (de) 2002-03-13 2008-05-15 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase- inhibitoren
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
CN100522166C (zh) 2002-04-18 2009-08-05 先灵公司 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
DE10319435B4 (de) * 2003-04-25 2018-07-26 Whitecryption Corporation Verfahren zur Verarbeitung von Daten zum Schutz eines Softwareprogramms vor Rekonstruktion
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1744751A4 (en) 2004-03-18 2010-03-10 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
DE102004035672A1 (de) 2004-07-22 2006-03-30 Windmöller & Hölscher Kg Verkürzte Stapelbildung
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004054053A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2007070760A2 (en) 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
KR20080080201A (ko) 2005-12-21 2008-09-02 쉐링 코포레이션 히스타민 ｈ3 길항제로서 유용한 치환된 아닐린 유도체
WO2007075524A2 (en) 2005-12-22 2007-07-05 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
WO2007087068A2 (en) 2006-01-13 2007-08-02 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
WO2007103456A2 (en) 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
AU2007231594A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
US20090247499A1 (en) * 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
EP2065369A4 (en) 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
WO2008075019A1 (en) 2006-12-18 2008-06-26 7Tm Pharma A/S Modulators of cb1 receptors
US7648979B2 (en) 2007-02-07 2010-01-19 Hoffmann-La Roche Inc. 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
US7507736B2 (en) 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2008150470A1 (en) 2007-05-31 2008-12-11 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
WO2008150447A1 (en) 2007-05-31 2008-12-11 Euro-Celtique S.A. Amide compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AU2008307572A1 (en) 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
EP2300432B1 (en) 2012-10-03
WO2010007073A1 (en) 2010-01-21
ES2396962T3 (es) 2013-03-01
EP2346828B1 (en) 2012-10-03
US8530478B2 (en) 2013-09-10
EA201170209A1 (ru) 2011-08-30
GB0813142D0 (en) 2008-08-27
US20100022555A1 (en) 2010-01-28
CA2730471C (en) 2016-12-06
JP2011528020A (ja) 2011-11-10
ES2396960T3 (es) 2013-03-01
WO2010007072A1 (en) 2010-01-21
MX2011000600A (es) 2011-05-24
JP2011528019A (ja) 2011-11-10
CN102099337A (zh) 2011-06-15
JP5688850B2 (ja) 2015-03-25
TW201016677A (en) 2010-05-01
AU2009272762A1 (en) 2010-01-21
AR072809A1 (es) 2010-09-22
KR20110031199A (ko) 2011-03-24
EP2346828A1 (en) 2011-07-27
AU2009272762B2 (en) 2013-08-15
IL210446A0 (en) 2011-03-31
EA018621B1 (ru) 2013-09-30
US8536183B2 (en) 2013-09-17
PL2300432T3 (pl) 2013-03-29
UY31990A (es) 2010-01-05
JP5543966B2 (ja) 2014-07-09
US20110130379A1 (en) 2011-06-02
ZA201100014B (en) 2011-09-28
EP2300432A1 (en) 2011-03-30
US20120302746A1 (en) 2012-11-29
IL210446A (en) 2014-01-30
CN102099337B (zh) 2013-08-21
KR101599087B1 (ko) 2016-03-02
US8288388B2 (en) 2012-10-16
CA2730471A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
BRPI0916622A2 (pt) derivados de piperazina usados como moduladores de canal de cálcio cav2,2
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112012008823B8 (pt) compostos que modulam receptor de androgênio, composição farmacêutica compreendendo os ditos compostos e usos dos mesmos para a prevenção ou tratamento de distúrbios dependentes de receptores de androgênio
SV2009003236A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas
CL2012001072A1 (es) Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas.
BR112012011427B8 (pt) moduladores seletivos de receptor de esfingosina 1 fosfato, seu uso, e composição
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
BR112012016376A2 (pt) compostos de pirrolo-aminopirimida substituída
BR112013026308A2 (pt) Compostos de benzeno substituídos
BRPI0915084B8 (pt) composto, e, composição farmacêutica
BR112015008480A2 (pt) compostos de benzeno substituído
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
NI201100056A (es) Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyética y su uso para tratar enfermedades mediadas por prostaglandina d2.
UY30610A1 (es) Moduladores de mglur5
DK2243772T3 (da) Hidtil ukendte P2X7R-antagonister og deres anvendelse
BRPI1007092B8 (pt) Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2523 DE 14-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]